[
    [
        {
            "time": "",
            "original_text": "贝达药业（300558）2021中报点评：业绩符合预期，凯美纳+贝美纳双驱动，持续巩固非小细胞肺癌领域优势【东吴医药朱国广团队】",
            "features": {
                "keywords": [
                    "贝达药业",
                    "凯美纳",
                    "贝美纳",
                    "双驱动",
                    "非小细胞肺癌",
                    "业绩符合预期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业（300558）2021中报点评：业绩符合预期，凯美纳+贝美纳双驱动，持续巩固非小细胞肺癌领域优势【东吴医药朱国广团队】",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "【黑科技】贝达药业万江先生：做好药，向国家标准靠拢",
            "features": {
                "keywords": [
                    "贝达药业",
                    "万江",
                    "国家标准"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "【黑科技】贝达药业万江先生：做好药，向国家标准靠拢",
                "Correlation": 7,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业恩沙替尼上半年销售收入 5497 万元，埃克替尼卖了 10.8 亿元",
            "features": {
                "keywords": [
                    "贝达药业",
                    "恩沙替尼",
                    "埃克替尼",
                    "销售收入"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业恩沙替尼上半年销售收入 5497 万元，埃克替尼卖了 10.8 亿元",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "15个药被限制使用",
            "features": {
                "keywords": [
                    "药品",
                    "限制使用"
                ],
                "sentiment_score": -0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "15个药被限制使用",
                "Correlation": 3,
                "Sentiment": 4,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "15个药品遭限用！正大天晴首超恒瑞 5大产品销售暴涨超50%",
            "features": {
                "keywords": [
                    "药品",
                    "限用",
                    "正大天晴",
                    "恒瑞",
                    "销售暴涨"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "15个药品遭限用！正大天晴首超恒瑞 5大产品销售暴涨超50%",
                "Correlation": 2,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)：业绩符合预期 研发稳步推进",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩符合预期",
                    "研发稳步推进"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)：业绩符合预期 研发稳步推进",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "西南证券维持贝达药业持有评级：业绩靓丽，重点品种增长趋势良好",
            "features": {
                "keywords": [
                    "贝达药业",
                    "西南证券",
                    "持有评级",
                    "业绩靓丽",
                    "增长趋势良好"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "西南证券维持贝达药业持有评级：业绩靓丽，重点品种增长趋势良好",
                "Correlation": 8,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "贝达药业(300558)2021年中报点评：埃克恩沙双驱动 多个产品进入报批阶段",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克恩沙",
                    "双驱动",
                    "产品报批"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558)2021年中报点评：埃克恩沙双驱动 多个产品进入报批阶段",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "研发投入不遗余力 已摆脱“单腿走路” 贝达药业上半年净利润增五成",
            "features": {
                "keywords": [
                    "贝达药业",
                    "研发投入",
                    "净利润增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "研发投入不遗余力 已摆脱“单腿走路” 贝达药业上半年净利润增五成",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "国金证券维持贝达药业买入评级：业绩稳健增长，恩沙替尼或将用于一线治疗",
            "features": {
                "keywords": [
                    "贝达药业",
                    "国金证券",
                    "买入评级",
                    "恩沙替尼",
                    "一线治疗"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "国金证券维持贝达药业买入评级：业绩稳健增长，恩沙替尼或将用于一线治疗",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 8,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]